A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 368,152 shares of IOVA stock, worth $3.44 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
368,152
Previous 407,429 9.64%
Holding current value
$3.44 Million
Previous $6.04 Million 51.11%
% of portfolio
0.16%
Previous 0.33%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$7.78 - $14.19 $305,575 - $557,340
-39,277 Reduced 9.64%
368,152 $2.95 Million
Q1 2024

Apr 17, 2024

BUY
$7.59 - $17.47 $921,388 - $2.12 Million
121,395 Added 42.44%
407,429 $6.04 Million
Q4 2023

Jan 10, 2024

BUY
$3.3 - $8.89 $348,278 - $938,241
105,539 Added 58.47%
286,034 $2.33 Million
Q3 2023

Oct 27, 2023

SELL
$4.44 - $8.79 $4,599 - $9,106
-1,036 Reduced 0.57%
180,495 $821,000
Q2 2023

Aug 09, 2023

BUY
$5.36 - $9.06 $5,590 - $9,449
1,043 Added 0.58%
181,531 $1.28 Million
Q1 2023

Apr 20, 2023

BUY
$5.53 - $8.22 $60,730 - $90,272
10,982 Added 6.48%
180,488 $1.1 Million
Q4 2022

Jan 12, 2023

BUY
$5.62 - $10.0 $434,161 - $772,530
77,253 Added 83.74%
169,506 $1.08 Million
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $78,460 - $107,934
8,233 Added 9.8%
92,253 $884,000
Q2 2022

Jul 19, 2022

BUY
$6.38 - $18.33 $225,233 - $647,103
35,303 Added 72.47%
84,020 $928,000
Q1 2022

Apr 26, 2022

BUY
$12.38 - $19.1 $238,129 - $367,388
19,235 Added 65.24%
48,717 $811,000
Q4 2021

Feb 14, 2022

BUY
$16.55 - $27.63 $487,927 - $814,587
29,482 New
29,482 $563,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.48B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Hennion & Walsh Asset Management, Inc. Portfolio

Follow Hennion & Walsh Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.